13 August 2018 - The FDA on Friday approved the first-ever RNA interference medicine — the latest in a rapidly growing series of gene therapies with six-digit price tags. Expect several dozen more within a few years.

Onpattro is now the only approved treatment for nerve damage related to a rare genetic disease. Alnylam, the Boston biotech that developed it, said the infusion would have an average list price of $450,000 a year. President Barry Greene said the company is getting payers on board with value-based pricing agreements. 

"If a patient is treated and does well," Greene said on an investor call Friday, "we deserve payment in full.” If assessments down the line show a patient doing “less well,” he said, the drug will be discounted.

Read Politico article